| Q36519986 | A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia |
| Q38579008 | Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG). |
| Q33425372 | An open-label expanded-access trial of bendamustine in patients with rituximab-refractory indolent non-Hodgkin lymphoma or previously untreated chronic lymphocytic leukemia: BEND-ACT |
| Q38676408 | Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review |
| Q33409149 | Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice. |
| Q88661825 | Cells, cytokines, chemokines, and cancer stress: A biobehavioral study of patients with chronic lymphocytic leukemia |
| Q38424831 | Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial |
| Q47094907 | Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification |
| Q52646820 | Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. |
| Q26775986 | Chronic Lymphocytic Leukemia in the Elderly, Which Investigations Are Necessary: A Map for the Practicing Oncologist |
| Q37903038 | Chronic lymphocytic leukemia in less fit patients: "slow-go". |
| Q34272532 | Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model |
| Q36826893 | Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015 |
| Q35110582 | Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia |
| Q43242768 | Current and emerging treatments for chronic lymphocytic leukaemia |
| Q33439818 | Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial |
| Q38791698 | First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study. |
| Q35794457 | Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach |
| Q34008866 | Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. |
| Q28306347 | Idelalisib and rituximab in relapsed chronic lymphocytic leukemia |
| Q38850667 | Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma |
| Q48070488 | Impact of active surveillance, chlorambucil, and other therapy on health-related quality of life in patients with CLL/SLL in the Netherlands |
| Q39475634 | Individual differences in physical symptom burden and psychological responses in individuals with chronic lymphocytic leukemia |
| Q34009041 | Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia |
| Q91525913 | Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience |
| Q34255124 | Lycorine sensitizes CD40 ligand-protected chronic lymphocytic leukemia cells to bezafibrate- and medroxyprogesterone acetate-induced apoptosis but dasatanib does not overcome reported CD40-mediated drug resistance. |
| Q36251887 | Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach |
| Q36845277 | Practical approach to management of chronic lymphocytic leukemia |
| Q37879960 | Presenting features and outcome of chronic lymphocytic leukemia patients diagnosed at age 80 years or more. An ICLLSG study |
| Q37801267 | Prognostic factors in chronic lymphocytic leukemia-what do we need to know? |
| Q33394308 | Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients |
| Q38982682 | Targeted Therapy in Chronic Lymphocytic Leukemia (CLL). |
| Q38126946 | The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy |
| Q28087378 | Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia |
| Q53244764 | Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma. |
| Q38132818 | Treatment of elderly patients with chronic lymphocytic leukemia: an unmet cinical need. |
| Q37974861 | Treatment of older patients with chronic lymphocytic leukemia |
| Q33846793 | Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database |
| Q96134163 | Updates from the American Society of Hematology 2019 annual meeting: practice-changing studies in treatment-naïve chronic lymphocytic leukemia |
| Q54407620 | Valproic acid enhances fludarabine-induced apoptosis mediated by ROS and involving decreased AKT and ATM activation in B-cell-lymphoid neoplastic cells. |
| Q36161529 | Value of Different Comorbidity Indices for Predicting Outcome in Patients with Acute Myeloid Leukemia |